Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months ...
Dyne’s exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at ...
Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy December ...
Placebo-controlled Phase 2 study will evaluate SAT-3247 treatment over three months among ambulatory children with Duchenne- Study endpoints include safety and tolerability, effect on muscle force and ...
Dyne Therapeutics intends to submit a biologics licence application to the FDA for accelerated approval in Q2 2026.
Dyne Therapeutics plans to submit its next-gen Duchenne muscular dystrophy drug to the FDA after a successful trial.
Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy, challenger from Massachusetts biotech Dyne ...
Adult skeletal muscle is a tissue with a high capacity for regeneration due to the existence of stem cell population, termed ...
Capricor Therapeutics, Inc. soars 450% on positive HOPE-3 DMD results. Discover market impact, growth potential, and risks.
Detailed price information for Satellos Bioscience Inc (MSCLF) from The Globe and Mail including charting and trades.
Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance ...
Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved dosing in Cohort 8 of ENDEAVOR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback